Compare Oscar Health Inc (OSCR) vs Royal Bank of Canada (RY) Price & Performance

Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.

Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.

Royal Bank of Canada (RY) trades at $209.00, down 0.76% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.07 per share, beating estimates of $2.89, continuing a trend of quarterly beats. Revenue growth accelerated to $66.53 billion in 2025, with net income margin improving to 32.01% and ROE at 17.2%. Recent corporate actions include dividend declarations of $1.76 per share payable in November 2026.

RY demonstrates solid fundamental strength with consistent earnings outperformance and robust profitability metrics. The stock faces valuation concerns with a P/E of 18.23 and P/S of 5.69, while analyst sentiment remains mixed with 43% buy ratings versus 53% hold. Key risks include stretched bank valuations and macroeconomic sensitivity, but the company's diversified business model and record earnings provide stability for long-term investors.